Drug Profile
Orellanine
Alternative Names: ONC-175Latest Information Update: 09 Feb 2022
Price :
$50
*
At a glance
- Originator Sahlgrenska University Hospital
- Developer Oncorena Holding
- Class Antineoplastics; Biological toxins; Mycotoxins; Oxides; Pyridines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Renal cancer
Most Recent Events
- 03 Feb 2022 Phase-I/II clinical trials in Renal cancer (Late-stage disease, Metastatic disease) in Sweden (IV)
- 02 Mar 2021 Orellanine is still in preclinical trials for Renal cancer in Sweden
- 02 Mar 2021 Swedish Medical Products Agency approved orellanine to commence phase I/II trial in patients with Renal cancer on dialysis